Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today
In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous system, were trading 13.9% higher as of 1:35 p.m. EDT on Wednesday.
Here's a review of the key financial numbers from the second quarter:
Acadia also shared a few non-financial highlights from the quarter with investors:
Source: Fool.com
Acadia Pharmaceuticals Aktie
25,59 €
0,08 %
Starke Bevorzugung von Acadia Pharmaceuticals in der Community mit ausschließlich Buy-Einschätzungen.
Das Kursziel von 29 € für Acadia Pharmaceuticals weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 25.59 € hin.
